Chronic Kidney Disease (CKD) Clinical Trial
Official title:
Factor XA - Inhibition in RENal Patients With Non-valvular Atrial Fibrillation - Observational Registry
The multicenter registry will collect clinical data from 1600 patients with non valvular atrial fibrillation (NVAF) and chronic kidney disease (eGFR 15-49 mL/min per 1.73 m2). The overall objective of this registry is to assess chronic kidney disease (CKD) progression and clinical outcomes with regard to anticoagulation strategies in NVAF patients with eGFR 15-49 mL/min per 1.73 m2 in routine clinical practice.
This is a prospective registry allowing a structured, non-interventional collection of data. Participating physicians will not be subject to any instructions with regard to the diagnosis and therapy of their patients. All patient treatment is carried out within clinical routine, at the discretion of the physician and according to existing treatment guidelines. This registry will be carried out as an investigator-initiated, multicentre, prospective, non-interventional and observational registry at approximately 160 sites in Germany, Austria, Switzerland, France, Belgium and Luxembourg. The registry will collect clinical data of approximately 1600 patients with CKD (eGFR 15-49 mL/min per 1.73 m2) and NVAF receiving rivaroxaban, OAC with VKA, or no AC therapy, who are prospectively followed for a flexible duration with a minimal follow-up duration of 12 months until study end is announced (planned minimum 360 days / planned maximum 84 months). The plan of the registry is to include at least 1600 patients with CKD and NVAF and rivaroxaban therapy or VKA therapy or no AC therapy. The aim is to include at least 700 patients with rivaroxaban therapy and VKA therapy, respectively. Into the exploratory treatment arm of patients receiving no AC therapy about 100 patients will be included. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05422755 -
The Clinical Study to Evaluate Immunogenicity of Epodion® in Anemia Associated With CKD Patients
|
||
| Completed |
NCT01693029 -
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
|
Phase 3 | |
| Recruiting |
NCT04064827 -
A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)
|
Phase 3 | |
| Completed |
NCT02218099 -
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease
|
Phase 1/Phase 2 | |
| Completed |
NCT02276742 -
Lifestyle Management of CKD in Obese Diabetic Patients
|
N/A | |
| Completed |
NCT01222234 -
Impact of Vitamin D Therapies on Chronic Kidney Disease
|
N/A | |
| Recruiting |
NCT05106387 -
An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive A Kidney Transplant
|
||
| Completed |
NCT05373303 -
The Clinical Study for Evaluating The Safety And Efficacy Of Epodion®
|
N/A | |
| Completed |
NCT01247311 -
Vitamin D and the Health of Blood Vessels in Kidney Disease
|
N/A | |
| Completed |
NCT04042350 -
Retrospective Analysis Assessing Clinical Risk Factors for Cardiovascular Events and Mortality and Development of a Risk Calculator in Chronic Kidney Disease Stage 5 on Dialysis
|
||
| Completed |
NCT02733328 -
Assessment of Plasma and NGAL for the Early Prediction of Acute Kidney Injury After Cardiac Surgery in Adults Study
|
||
| Completed |
NCT02341664 -
Patient and Provider Assessment of Lipid Management Registry
|
||
| Enrolling by invitation |
NCT06322641 -
A Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among Nephrologists
|
||
| Completed |
NCT05755373 -
A Multinational Survey-based Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among Cardiologists
|
||
| Completed |
NCT02678000 -
Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function
|
Phase 2 | |
| Completed |
NCT02185911 -
Observational Study of Correction of Anaemia With Darbepoetin Alfa at QM Dosing Interval in Patients With CKD Not on Dialysis
|
N/A | |
| Terminated |
NCT03226899 -
A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment
|
Phase 4 | |
| Completed |
NCT02504294 -
A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis
|
Phase 3 | |
| Active, not recruiting |
NCT04094831 -
Community-based Screening of Chronic Kidney Disease (CKD) and Measure the Impact of Health Education
|
N/A | |
| Completed |
NCT01810939 -
A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)
|
Phase 3 |